SCHEMBL7130546

SCHEMBL7130546

O=S1(=O)CC(Sc2ccccc2)c2cc(OCc3cccnc3)ccc21

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.42
CREBBP Q92793 1/20 0.42
MAPK1 P28482 2/20 0.41
GPR132 Q9UNW8 9/20 0.39
CMKLR2 P46091 1/20 0.39
CMKLR1 Q99788 1/20 0.39
CA2 P00918 1/20 0.39
CA5A P35218 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRM2 Q14416 1/20 0.38
SNRNP200 O75643 1/20 0.38
CSF1R P07333 1/20 0.38
IKBKB O14920 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135165 0.93 BRD4 (0.43) BRD4CREBBPMAPK1GPR132CMKLR2
SCHEMBL7130056 0.89 SERPINE1 (0.43) GRM2
SCHEMBL7159904 0.89 MAPK1 (0.41) BRD4CREBBPMAPK1GPR132SMN1; SMN2
SCHEMBL7132324 0.88 MAPK1 (0.42) BRD4CREBBPMAPK1GPR132CMKLR2
SCHEMBL7130539 0.88 MAPK1 (0.41) BRD4CREBBPMAPK1GPR132CMKLR2
SCHEMBL7135162 0.83 MAPK1 (0.43) BRD4CREBBPMAPK1GPR132CMKLR2
SCHEMBL7126381 0.82 CA2 (0.48) CA2CA5A
SCHEMBL7134456 0.80 GRM2 (0.41) BRD4CREBBPMAPK1GPR132CMKLR2
SCHEMBL7128603 0.80 HTR1A (0.44) BRD4MAPK1ALDH1A1LMNAIKBKB
SCHEMBL7124904 0.80 HTR1A (0.44) BRD4MAPK1ALDH1A1LMNAIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO BRD4 3494/4885CREBBP 1054/4885MAPK1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.